Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction

Yu,Jingbin; Zhang,Lei; Zhang,Hui

doi:10.3892/etm.2020.8438

Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction

Authors:
- Jingbin Yu
- Lei Zhang
- Hui Zhang
View Affiliations

Affiliations: Department of Cardiology, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China
Published online on: January 27, 2020 https://doi.org/10.3892/etm.2020.8438
Pages: 2053-2058
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effect of atorvastatin combined with routine therapy on the expression of hypoxia inducible factor (HIF‑1) and vascular endothelial growth factor (VEGF) in rats with acute myocardial infarction (AMI) and its therapeutic effect were investigated. The rat models of acute myocardial infarction were established and divided into routine therapy, study, model, single drug and control group according to the treatment plan, with 10 cases in each group. Enzyme‑linked immunosorbent assay (ELISA) was used to detect the concentration of HIF‑1 and VEGF in serum of rats before treatment (T0), and 3 days (T1), 5 days (T2) and 7 days (T3) after treatment, and the cardiac function was measured at the same time. The concentrations of HIF‑1 and VEGF in serum of the study group and the routine therapy group after treatment were significantly higher than those before treatment. The concentrations of HIF‑1 and VEGF in serum of model group at T0 were significantly lower than those at T3 (P<0.05). After treatment, the concentrations of HIF‑1 and VEGF in serum of the study group were significantly higher than those of the routine therapy, the model and the control group (P<0.05). One week after administration, there were significant differences in the left ventricular function among the five groups (P<0.001). The left ventricular function in the study group was better than that in the routine therapy, model and control group. The levels of HIF‑1 and VEGF in the serum of rats with myocardial infarction were negatively correlated with LVIDs and LVIDd, and positively correlated with LVEF% and LVFS%. In conclusion, atorvastatin combined with routine therapy can better reduce serum HIF‑1 and VEGF levels and improve the left ventricular function in rats than routine therapy.

View Figures

View References

1	Hu C, Tkebuchava T and Hu D: Managing acute myocardial infarction in China. Eur Heart J. 40:1179–1181. 2019. View Article : Google Scholar : PubMed/NCBI
2	Reed GW, Rossi JE and Cannon CP: Acute myocardial infarction. Lancet. 389:197–210. 2017. View Article : Google Scholar : PubMed/NCBI
3	Yang CJ, Chen PC, Lin CS, Tsai CL and Tsai SH: Thrombolytic therapy-associated acute myocardial infarction in patients with acute ischemic stroke: A treatment dilemma. Am J Emerg Med. 35:804.e1–804.e3. 2017. View Article : Google Scholar
4	Kassimis G and Picard F: Resorbable magnesium scaffolds in acute myocardial infarction patients: ‘To be or not to be’? Cardiology. 142:97–99. 2019. View Article : Google Scholar : PubMed/NCBI
5	Hoeke G, Wang Y, van Dam AD, Mol IM, Gart E, Klop HG, van den Berg SM, Pieterman EH, Princen HMG, Groen AK, et al: Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. Atherosclerosis. 267:116–126. 2017. View Article : Google Scholar : PubMed/NCBI
6	McCarthy CP, Vaduganathan M, McCarthy KJ, Januzzi JL Jr, Bhatt DL and McEvoy JW: Left ventricular thrombus after acute myocardial infarction: Screening, prevention, and treatment. JAMA Cardiol. 3:642–649. 2018. View Article : Google Scholar : PubMed/NCBI
7	Ma Y, Kong L, Qi S and Wang D: Atorvastatin blocks increased l-type Ca²⁺ current and cell injury elicited by angiotensin II via inhibiting oxide stress. Acta Biochim Biophys Sin (Shanghai). 48:378–384. 2016. View Article : Google Scholar : PubMed/NCBI
8	Gavazzoni M, Gorga E, Derosa G, Maffioli P, Metra M and Raddino R: High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction. Drug Des Devel Ther. 11:3425–3434. 2017. View Article : Google Scholar : PubMed/NCBI
9	Li Q, Zhao YG, Wang Z, Jiang HP, Liu WB and Cao BF: Effects of first high-dose atorvastatin loading in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Am J Ther. 25:e291–e298. 2018. View Article : Google Scholar : PubMed/NCBI
10	Xu XR, Li KB, Wang P, Xu L, Liu Y, Yang ZS and Yang XC: The impact of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention. Zhonghua Nei Ke Za Zhi. 55:932–936. 2016.(In Chinese). PubMed/NCBI
11	Koyasu S, Kobayashi M, Goto Y, Hiraoka M and Harada H: Regulatory mechanisms of hypoxia-inducible factor 1 activity: Two decades of knowledge. Cancer Sci. 109:560–571. 2018. View Article : Google Scholar : PubMed/NCBI
12	Zhang N, Chen J, Ferraro GB, Wu L, Datta M, Jain RK, Plotkin SR, Stemmer-Rachamimov A and Xu L: Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol. 299:326–333. 2018. View Article : Google Scholar : PubMed/NCBI
13	Cheng C, Li P, Wang YG, Bi MH and Wu PS: Study on the expression of VEGF and HIF-1α in infarct area of rats with AMI. Eur Rev Med Pharmacol Sci. 20:115–119. 2016.PubMed/NCBI
14	Parisi Q, Biondi-Zoccai GG, Abbate A, Santini D, Vasaturo F, Scarpa S, Bussani R, Leone AM, Petrolini A, Silvestri F, et al: Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. Int J Cardiol. 99:337–339. 2005. View Article : Google Scholar : PubMed/NCBI
15	Eyarefe OD, Ologunagba FM and Emikpe BO: Wound healing potential of natural honey in diabetic and non-diabetic wistar rats. Afr J Biomed Res. 17:15–21. 2014.
16	Helft G, Georges JL, Mouranche X, Loyeau A, Spaulding C, Caussin C, Benamer H, Garot P, Livarek B, Teiger E, et al e-MUST and CARDIO-ARSIF Registries, : Outcomes of primary percutaneous coronary interventions in nonagenarians with acute myocardial infarction. Int J Cardiol. 192:24–29. 2015. View Article : Google Scholar : PubMed/NCBI
17	Chen WW, Gao RL, Liu LS, Zhu ML, Wang W, Wang YJ, Wu ZS, Li HJ, Gu DF, Yang YJ, et al: China cardiovascular diseases report 2015: A summary. J Geriatr Cardiol. 14:1–10. 2017.PubMed/NCBI
18	Yamamoto K, Sakakura K, Akashi N, Watanabe Y, Noguchi M, Seguchi M, Taniguchi Y, Ugata Y, Wada H, Momomura SI, et al: Novel acute myocardial infarction risk stratification (nARS) system reduces the length of hospitalization for acute myocardial infarction. Circ J. 83:1039–1046. 2019. View Article : Google Scholar : PubMed/NCBI
19	Mensah K, Mocanu MM and Yellon DM: Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol. 45:1287–1291. 2005. View Article : Google Scholar : PubMed/NCBI
20	Du ZB, Mao RM, Gao WM, Mi L, Cao ZP and Zhu BL: Early expression of hypoxia-inducible factor-1 alpha after acute myocardial ischemia in rats. Fa Yi Xue Za Zhi. 28:327–332. 2012.(In Chinese). PubMed/NCBI
21	Chen Y, Tao Y, Zhang L, Xu W and Zhou X: Diagnostic and prognostic value of biomarkers in acute myocardial infarction. Postgrad Med J. 95:210–216. 2019. View Article : Google Scholar : PubMed/NCBI
22	Li M, Cui Y, He W, Deng X, Wang Y, Cai M, Wang Y, Pei J, Mei X and Wu P: Effects of triple-mutated hypoxia-inducible factor-1α on angiogenesis and cardiac function improvement in rats with myocardial infarction. Cell Physiol Biochem. 50:2329–2340. 2018. View Article : Google Scholar : PubMed/NCBI
23	Wang L, Yang J, Zheng J and Gu X: Acute myocardial infarction in pregnancy: Spasm caused by hyperthyroidism? J Int Med Res. 47:2269–2273. 2019. View Article : Google Scholar : PubMed/NCBI
24	Sivri N, Tekin G, Yalta K, Aksoy Y, Senen K and Yetkin E: Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiol Pol. 71:1042–1047. 2013. View Article : Google Scholar : PubMed/NCBI
25	Nordøy A, Svensson B and Hansen JB: Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. J Thromb Haemost. 1:690–697. 2003. View Article : Google Scholar : PubMed/NCBI
26	Otto CM: Heartbeat: Improving acute myocardial infarction outcomes in women. Heart. 105:501–502. 2019. View Article : Google Scholar : PubMed/NCBI
27	Wang M, Vaez M, Dorner TE, Rahman S, Helgesson M, Ivert T and Mittendorfer-Rutz E: Risk factors for subsequent work disability in patients with acute myocardial infarction. Eur J Public Health. 29:531–540. 2019. View Article : Google Scholar : PubMed/NCBI
28	Kumar M, Rehan HS, Puri R, Yadav M and Gupta LK: Randomized controlled trial comparing the efficacy of daily and every other day atorvastatin therapy and its correlation with serum hydroxymethylglutaryl-CoA reductase enzyme levels in naïve dyslipidemic patients. Indian Heart J. 70 (Suppl 3):S64–S67. 2018. View Article : Google Scholar : PubMed/NCBI
29	Komarova IS, Karova LB, Andreeva NV, Cherkasova NA and Zhelnov VV: Effect of myocardial reperfusion on ischemic mitral regurgitation in patients with acute myocardial infarction. Kardiologiia. 59:18–25. 2019. View Article : Google Scholar : PubMed/NCBI
30	Ielasi A, Cerrato E, Geraci S, Campo G, Garro N, Leoncini M, Sganzerla P, Granata F, Ruggiero R, Varbella F, et al: Sirolimus-eluting magnesium resorbable scaffold implantation in patients with acute myocardial infarction. Cardiology. 142:93–96. 2019. View Article : Google Scholar : PubMed/NCBI